CommercialCoverageMedium impact
Implantable and Invasive Neuromodulation Systems 1.01.60
Excellus BlueCross BlueShield·Pain Management, Neurosurgery, Neurology +2 more·Durable Medical Equipment & Supplies
Effective date
May 21, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has classified all implantable and invasive neuromodulation systems as investigational, meaning they are not covered benefits. This includes peripheral nerve stimulation systems, restorative neurostimulation devices like ReActiv8, and percutaneous electrical nerve stimulation treatments.
Action Required
By May 21, 2026: Billing team must update system to deny coverage for all implantable and invasive neuromodulation procedures for Excellus BlueCross BlueShield members. Flag these services as investigational/non-covered in billing software. Inform providers that these devices and procedures will not be reimbursed by this payer. Verify patient benefits and discuss alternative treatments or self-pay options before scheduling procedures.